Focused on designing and validating the therapeutic impact of Myc-tag peptides in vitro and in vivo; comparing and contrasting possible Myc inhibitors in murine cancer models (lung cancer, glioma, metastatic breast cancer, melanoma and multiple myeloma). And studying the effects of Myc inhibition in immune response and tumour environment.

From a strategic point of view, the group is working on designing and characterising new cell-penetrating peptides for oncology treatment. As well as preclinical validation of a new generation of peptides based on Omomyc as a therapeutic strategy in melanoma, multiple myeloma and lung, brain and breast cancer. Determining the therapeutic effect of inhibiting Myc in breast cancer metastasis, and defining the function of inflammatory Myc effectors in tumour formation and maintenance.

Visit the research group’s page


Subscribe to our newsletters and be a part of Vall d'Hebron Campus

Select the newsletter you want to receive:

By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Vall d’Hebron University Hospital Foundation – Research Institute.
Purpose: Manage the user’s contact information.
Legitimisation: Express acceptance of the privacy policy.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.